Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy

Fig. 3

dCAR-engineered T cells on tumor clearance in vivo. To investigate the activity of dCAR-T cells in vivo, we evaluated the pancreatic cancer regression in immunodeficient mice. a Schematic of the mouse treatment strategy. Day 0, all tumor cells, including AsPC-1 cells, HT29 cells, U87 cells, or PANC-1 cells, were injected into nude mice intravenously (i.v.). Mice were treated with various effector cells at 7 days after tumor injection, and then the survival of target cells, cytokine release, and T cell number were detected. b After effector cell injection, the tumor regression was followed by in vivo living image of the mean fluorescence intensity from RFP-engineered tumor cells (n = 5). c Cytotoxic activities of engineered T cells were characterized based on the mock T cell cytotoxicity at 35 days after tumor injection. Data showed that the relative cytotoxic activity of effector cells is approximately 93.8%, having a significant difference relative to that of mock T cells (n = 5, error bars denote standard deviation). d The proliferation of modified T cells was measured in vivo. Data showed that dCAR-T cells provided significantly greater proliferation compared with the single-receptor structure, including Cζ-CAR and MBB-CAR (n = 5, error bars denote standard deviation). e, f Effector cells released various cytokines, including IL-2, TNFα, IL-6, and IFNγ. In our experiment, significant cytokine production had achieved in mice treated with dCAR-T cells, which was similar to that of conventional CAR-T cells (CEA-CAR T or MSLN-CAR T) (n = 5, error bars denote standard deviation)

Back to article page